|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅱ study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer显示文摘AIM: To test protracted irinotecan infusion plus a low-dose cisplatin in this Phase Ⅱ trial to decrease its toxic-ity. METHODS: The eligibility criteria were: (1) histologi-cally proven measurable gastric cancer; (2) performance status of 0 or 1; (3) no prior chemotherapy or comple-tion of prior therapy at least 4 wk before enrollment; (4) adequate function of major organs; (5) no other active malignancy; and (6) written informed consent. The regi-men consisted of irinotecan (60 mg/m2) on d 1 and 15 by 24-h infusion and cisplatin (10 mg/m2) on d 1, 2, 3, 15, 16, and 17. Treatment was repeated every 4 wk. RESULTS: Thirty-one patients were registered between April 2000 and January 2001. The response rate for all 31 patients, 20 patients without prior chemotherapy, and 11 patients with prior chemotherapy was 52% (16/31), 60% (12/20), and 36% (4/11), respectively. The median survival time was 378 d. The median number of courses given to all patients was 2. Grade 4 neutropenia oc-curred in 11 (35%) patients, while grade 3 to 4 diarrhea or nausea occurred in 1 (3%) and 3 (10%) patients, respectively. Fatigue was minimal as grade 1 fatigue was found only in 3 (10%) patients. Other adverse events were mild and no treatment-related deaths occurred.CONCLUSION: This regimen showed a high level of ac-tivity and acceptable toxicity in patients with metastatic gastric cancer. | Hiroshi Imamura Masataka Ikeda Hiroshi Furukawa Toshimasa Tsujinaka Kazumasa Fujitani Kenji Kobayashi Hiroyuki Narahara Michio Kato Haruhiko Imamoto Arimichi Takabayashi Hideaki Tsukuma | 2006 | World Journal of Gastroenterology2006，12，40： | 7 |
| 2 | Complete response to preoperative chemoradiotherapy in highly advanced gastric adenocarcinoma显示文摘This report presents a case of highly advanced gastric cancer that achieved a histologically complete response (CR) to preoperative chemoradiotherapy with S-1 plus low-dose Cisplatin. A 60-year-old male patient underwent FDG positron emission tomography (PET) during a routine health examination. The patient was found to have swollen paraaortic lymph nodes. Shortly thereafter, he was diagnosed with gastric carcinoma with a type 2 tumor in the antrum with paraaortic lymph node metastases based on FDG-PET, endoscopic examination and abdominal computed tomography. After the completion of chemoradiation therapy (CRT), the tumor and the paraaortic lymph node metastases disappeared. The patient underwent surgery 5 wk after the completion of CRT, including a subtotal gastrectomy with Rouxen-Y reconstruction, D3 lymph node dissection and a left adrenalectomy. No cancer cells were detected in the resected specimen either in the primary lesion or lymph nodes, thus confirming a pathologically CR to CRT (CR grade 3). The patient has been stable and well without any evidence of recurrence for 48 mo after surgery. Such a preoperative CRT regimen might therefore be very effective for treatment of some advanced gastric cancers. | Hironori Shigeoka Haruhiko Imamoto Yasumasa Nishimura Taro Shimono Hiroshi Furukawa Hiroshi Imamura Takushi Yasuda Hitoshi Shiozaki | 2010 | World Journal of Gastrointestinal Oncology2010，2，6： | 6 |
| 3 | The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry显示文摘雄激素在前列腺癌症致病起一个中央作用,并且因此病人的大多数对雄激素剥夺治疗作出回应。然而,病人们与好攻击的前列腺癌症趋于到恶化,它是被称为荷尔蒙倔强。识别调停的蛋白质前进到荷尔蒙倔强的状态,我们为病人的 sera 介绍的质量使用了蛋白质薄片技术。这研究与变形荷尔蒙倔强的前列腺癌症包括了 16 个病人开始与雄激素剥夺被对待治疗。浆液样品在五个次点从每个病人被收集:点 A,预告的处理;削尖 B,在前列腺特定的抗原(PSA ) 的天底水平;点 C, PSA 失败;点 D,早荷尔蒙倔强的阶段;并且削尖 E,晚荷尔蒙倔强的阶段。用提高表面的激光解吸附作用 / 电离 time-of-flight 团 spectrometry,我们执行了病人的 sera 介绍的蛋白质质量并且识别了与疾病前进增加了的 6 640-Da 山峰。目标蛋白质部分被净化,并且由氨基酸定序,山峰作为 apolipoprotein C-I 的碎片被识别(ApoC -- 我) 。浆液 ApoC -- 我蛋白质层次与疾病前进增加了。在 immunohistochemical 分析上, ApoC -- 我蛋白质被发现局部性到荷尔蒙倔强的癌症房间的细胞质。在这研究,我们在浆液 ApoC 显示出增加 -- 我蛋白质在他们的前进期间在前列腺癌症病人铺平到荷尔蒙倔强的状态,它建议那 ApoC -- 我蛋白质与前列腺癌症的前进有关。然而, ApoC 的准确角色 -- 我在前列腺癌症致病是不清楚的,进一步的研究被要求。 | Kaori Yamamoto-Ishikawa Hiroyoshi Suzuki Masahiko Nezu Naoto Kamiya Takashi Imamoto Akira Komiya Kazuyuki Sogawa Takeshi Tomonaga Fumlo Nomur Tomohiko Ichikawa | 2009 | Asian Journal of Andrology2009，11，3： | 3 |
| 4 | Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells 显示文摘 | Zambrowicz BP Imamoto A Fiering S | 1997 | Proc Natl Acad Sci USA1997，94，8： | 1 |
| 5 | Functional and geometrical interference and interdependency between the right and left ventricle in cor pulmonale:an experimental study on simultaneous measurement of biventricular geometry of acute right ventricular pressure overload显示文摘 | Yamashita H Onodera S Imamoto T | 1989 | Jpn Circ J1989，53，10： | 1 |
| 6 | Lewis Acid Catalyzed Highly Regio-and Stereocontrolled Trans-Hydrosilylation of Alkynes and Allenes显示文摘 | Imamoto T | 1999 | J Org Chem1999，64，： | 1 |
| 7 | Neuroendocrine differentiation in the progression of prostate cancer 显示文摘 | Komiya A Suzuki H Imamoto T | 2009 | Int J Urol2009，16，1： | 1 |
| 8 | Trimethylsilyl polyphosphate (PPSE), a useful reagent for the Becmann rearrangement显示文摘 | Imamoto T Yokoyama H Yokoyama M | 1981 | Tetrahedron Lett1981，22，19： | 1 |
| 9 | Preparation of enantiopure 2,2 ', 5, 5 '-tetramethyl 3,4-hexanediol and its use in catalytic enantioselective oxidation of sulfides to sulfoxides 显示文摘 | Yaoanoi Y Imamoto T | 1977 | Org Chem1977，62，24： | 1 |
| 10 | Syntheses of new C2- symmetric, optically active 1, 2- diols bearing tertiary alkyl groups 显示文摘 | Takeda T Imamoto T | 1999 | Tetrahedron : Asymraetry1999，10，16： | 1 |
| 11 | 显示文摘 | Yamaguchi S Ito O Imamoto N | 2011 | No Shinkei Geka2011，39，2： | 1 |
| 12 | Raf kinase inhibitory protein(RKIP):a physiological regulator and future therapeutic target显示文摘 | Zeng L Imamoto A Rosner MR | | 0，，10： | 1 |
| 13 | Minimally invasive esophagectomy with 10 cm thoracotomy assisted thoracoscopy for the thoracic esophageal cancer显示文摘 | Shiozaki H Imamoto H Shigeoka H | 2003 | Gan To Kagaku Ryoho2003，30，7： | 1 |
| 14 | Nucleocytoplasmic transport under stress conditions and its role in HSP70 chaperone systems 显示文摘 | Kose S Imamoto N | 2014 | Biochim Biophys Acta2014，1840，9： | 1 |
| 15 | Substrate temperature dependence of transparent conducting Al-doped ZnO thin films prepared by magnetron sputtering显示文摘 | Minami T Sato H Imamoto H | 1992 | Jpn J Appl Phys1992，31，3： | 1 |
| 16 | Transcriptional control of the endogenous myc proto oncogeneby antisense RNA显示文摘 | Yokoyama K Imamoto F | 1987 | PNAS USA1987，84，： | 1 |
| 17 | Two humangenes isolated by a novel method encode DNA-binding proteinscontaining a common region of homology 显示文摘 | SAKURA H MAEKAWA T IMAMOTO F | 1988 | Gene1988，73，2： | 1 |
| 18 | Beneficial effects of TDN-345, a novel Ca2+ antagonist, on ischemic brain injury and cerebrl glucose metabolism in experimental animal models with cerebrovascular lesions 显示文摘 | Nakayama T Nagisa Y Imamoto T | 1997 | Brain Res1997，762，12： | 1 |
| 19 | Anoxia/reoxygenation down-regulates the expression of E-cadherin in human colon cancer cell lines显示文摘 | SATOSHI KOKURA NIRIMASA YOSHIDA EIKO IMAMOTO | 2004 | Cancer Lett2004，211，1： | 1 |
| 20 | Carbon-carbon bond-forming reactions using cerium metal or organocerium(Ⅲ) reagents显示文摘 | IMAMOTO T HATANAKA Y TARAWAYANA Y | 1984 | J Org Chem1984，49，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员